AQST - Aquestive completes early-stage AQST-108 trial September, 30 2019 07:49 AM Aquestive Therapeutics Inc. Aquestive Therapeutics (NASDAQ:AQST) has completed its Phase 1 dose escalation proof-of-concept study in healthy subjects for AQST-108.More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Read more ...